Dolutegravir vs Raltegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by GlaxoSmithKline and partners
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)
Result source: NCT01263015
Raltegravir · Isentress
Marketed by Merck & Co.
NCT00293254 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.
Next expected readout: January 2028 · NCT02140255 (registry estimate)
Reported efficacy
Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)
Result source: NCT00293254
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dolutegravir | Raltegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 88% vs 85%vs RTGNCT0122782412 other results
| —Not posted · NCT01195467 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT01837277 | —Not posted · NCT01195467 |
| CD4 count, change (week 48) | 115 vs 156−41 vs placeboNCT0156889244 other results
| 98.4 vs 39.8+58.6 vs placeboNCT002932546 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Dolutegravir
- 88% vs 85%vs RTGNCT01227824
12 other results
- 90% vs 83% NCT01449929
- 88% vs 81% NCT01263015
- 90% vs 93% NCT02831673
- 93% vs 94% NCT02831764
- 71% vs 63% NCT01263015
- 77% vs 70% NCT01263015
- 79% vs 83% NCT02831673
- 84% vs 84% NCT02831764
- 84% vs 89% NCT02831673
- 88% vs 90% NCT02831764
- 92% vs 93% NCT02831673
- 94% vs 94% NCT02831764
- Raltegravir
- —Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)
- Dolutegravir
- —Not posted · NCT01837277
- Raltegravir
- —Not posted · NCT01195467
CD4 count, change (week 48)
- Dolutegravir
- 115 vs 156−41 vs placeboNCT01568892
44 other results
- 90.5 vs 125.5 NCT01568892
- 170 vs 146 NCT01568892
- 48 vs 135.5 NCT01568892
- 39 vs 117 NCT01568892
- 163 vs 174 NCT01568892
- 238.9 vs 257.5 NCT01227824
- 248.8 vs 230.7 NCT01910402
- 224.1 vs 239.8 NCT01227824
- 247.8 vs 264.2 NCT01227824
- 230.7 vs 191.4 NCT01910402
- 223.4 vs 241.3 NCT01227824
- 199.3 vs 204.2 NCT01227824
- 247.8 vs 278.6 NCT01227824
- 200.6 vs 163 NCT01910402
- 281.3 vs 292.9 NCT01227824
- 292.2 vs 286.2 NCT01227824
- 267.5 vs 209.5 NCT01263015
- 265.5 vs 216.2 NCT01263015
- 271.3 vs 235.3 NCT01263015
- 250.5 vs 208.1 NCT01263015
- 216.9 vs 177.8 NCT01263015
- 306.1 vs 269.6 NCT01263015
- 315.2 vs 272.1 NCT01263015
- 322.6 vs 286 NCT01263015
- 349.3 vs 298.9 NCT01263015
- 347 vs 311 NCT01263015
- 377.9 vs 327.2 NCT01263015
- 378.5 vs 331.6 NCT01263015
- 379.5 vs 333.3 NCT01263015
- 222.2 vs 217.7 NCT02831673
- 225.7 vs 217.2 NCT02831764
- 192.2 vs 175.1 NCT02831673
- 188.8 vs 163.2 NCT02831764
- 264.7 vs 253.8 NCT02831673
- 272 vs 264.6 NCT02831764
- 265 vs 230 NCT02259127
- 311 vs 230 NCT02259127
- 228 vs 230 NCT02259127
- 301.8 vs 303.2 NCT02831673
- 301.7 vs 296.6 NCT02831764
- 39 vs 28 NCT02263326
- 72 vs 230 NCT02259127
- 88 vs 75 NCT03991013
- 111 vs 101 NCT03851588
- Raltegravir
- 98.4 vs 39.8+58.6 vs placeboNCT00293254
6 other results
- 120.2 vs 49.4 NCT00293267
- 157.2 vs 54.2 NCT00293254
- 170.9 vs 71.0 NCT00293267
- 8.6 vs 21.9 NCT00772590
- 2.7 vs 21.9 NCT00772590
- 192 vs 205 NCT00762892
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Dolutegravir: 7 of 7 rows · Raltegravir: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dolutegravir Rows use multiple source trials | Raltegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL Induction | 214.7 vs 174.1 EFV/TDF/FTC cells/uL @ 16wk50 mg plus 600/300 mg once dailya NCT01263015 · Phase 3 · combination · HIV · phase 3 2 other source trials155.1 vs 173 RTG cells/uL @ 16wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 76.5 vs 70 placebo cells/uL @ 16wk50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence | 85.8 vs 39.9 placebo cells/uL @ 16wk400 mg b.i.d.a NCT00293254 · Phase 3 · combination 1 other source trial82.7 vs 31.3 placebo cells/uL @ 16wk400 mg b.i.d NCT00293267 · Phase 3 · combination |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 160 cells/uL @ 96wk50 mg BIDa,b NCT01328041 · Phase 3 1 other source trial286.5 cells/uL @ 96wk NCT01910402 · Phase 3 · registry result, not featured evidence | 261.6 cells/uL @ 96wka,b NCT02131233 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA LT 50 Copies responder rate · % of participants No placebo or comparator arm | 100% (n=149) @ 96wkc,d,b NCT01910402 · Phase 3 · registry result, not featured evidence | 90.6% (n=32) @ 96wkc,d,b NCT00939874 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 17.4%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results26%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 13.6%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 31.1%50 mg BID NCT01328041 · Phase 3 8.5% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 10.7% NCT04585737 · Phase 4 · registry result, not featured evidence 25.6%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 13.1%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 16.2%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 11.4%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 7.8%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 4.7%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence 0%50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 0%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 0%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 23.9% NCT01837277 · Phase 2/3 · registry result, not featured evidence 0%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 1.5% NCT03991013 · Phase 2 · registry result, not featured evidence 3.8% NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 23.7%400 mg b.i.d.f NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 17.5%400 mg b.i.d NCT00293267 · Phase 3 · combination 25.5%400 mg b.i.d. NCT00369941 · Phase 3 15.4% NCT01147107 · Phase 4 · registry result, not featured evidence 9.5% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence 38.5% NCT00939874 · Phase 4 · registry result, not featured evidence 0% NCT00843713 · Phase 4 · registry result, not featured evidence 22.2% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 27.3% NCT00870363 · Phase 4 · registry result, not featured evidence · combination 6.7%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 35.7% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 6.7%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 28.6%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 0%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 7.5%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 4.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 12.4%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results2.9%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 2.1%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 3.8%50 mg BID NCT01328041 · Phase 3 — NCT04880395 · Phase 4 · registry result, not featured evidence · combination — NCT04585737 · Phase 4 · registry result, not featured evidence —Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination —Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination —Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination —Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination — NCT02263326 · Phase 3 · registry result, not featured evidence · combination 7.7%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence — NCT01837277 · Phase 2/3 · registry result, not featured evidence —50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence —50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence — NCT03991013 · Phase 2 · registry result, not featured evidence — NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 0.9%400 mg b.i.d.f NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 0.4%400 mg b.i.d NCT00293267 · Phase 3 · combination 5%400 mg b.i.d. NCT00369941 · Phase 3 — NCT01147107 · Phase 4 · registry result, not featured evidence — NCT03374358 · Phase 4 · registry result, not featured evidence — NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence — NCT00939874 · Phase 4 · registry result, not featured evidence — NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination — NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence — NCT00762892 · Phase 4 · registry result, not featured evidence — NCT01335620 · Phase 4 · registry result, not featured evidence · combination 0%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 7.1%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination —Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence —Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination — NCT00631449 · Phase 4 · registry result, not featured evidence —1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination — NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 1.3%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 15.7%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results10%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 6.2%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg once daily NCT01449929 · Phase 3 14.9%50 mg once daily NCT01449929 · Phase 3 3.3%50 mg once daily NCT01449929 · Phase 3 25.1%50 mg BID NCT01328041 · Phase 3 9.9% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 8.1% NCT04585737 · Phase 4 · registry result, not featured evidence 7.7%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 8.2%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence 8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 2.1%DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 10.4%DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination 3.6%DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 10.8%DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 18%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 18.1%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 35.7%50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 26.2%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 10%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 14.9%Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 6.1%Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 9.8% NCT01837277 · Phase 2/3 · registry result, not featured evidence 6.9%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 3.1% NCT03991013 · Phase 2 · registry result, not featured evidence 0% NCT03851588 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence 7.1%Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | —400 mg b.i.d.f NCT00293254 · Phase 3 · combination show 27 more results34.8%400 mg b.i.d. NCT00293254 · Phase 3 · combination 41.8%400 mg b.i.d NCT00293267 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 20.3%400 mg b.i.d. NCT00369941 · Phase 3 21.1% NCT01147107 · Phase 4 · registry result, not featured evidence 0% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence 0%Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence 0%Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 0% NCT02383355 · Phase 4 · registry result, not featured evidence 13.5% NCT00939874 · Phase 4 · registry result, not featured evidence 3.8% NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 7.1% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 13.3%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 14.3%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 5.3%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 0%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination —Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mg plus 600/300 mg once dailye diarrhoea 22.7% nasopharyngitis 20.8% insomnia 17.9% NCT01263015 · Phase 3 · combination · HIV · phase 3 show 31 more results50 mg Once a Day upper respiratory tract infection 8% syphilis 7.1% viral upper respiratory tract infection 7.1% NCT01227824 · Phase 3 · HIV · phase 3 50 mg once daily viral upper respiratory tract infection 4.1% gastroenteritis 2.4% asthenia 1.6% NCT01449929 · Phase 3 insomnia/nightmares 3.9% alopecia 2% itching/rash/prurigo 2% NCT04880395 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 8.7% headache 8.1% urinary tract infection 6% NCT01910402 · Phase 3 · registry result, not featured evidence nausea 18.5% headache 11.7% diarrhoea 9.3% NCT01910402 · Phase 3 · registry result, not featured evidence covid-19 6.9% suspected covid-19 3.4% headache 3% NCT02831673 · Phase 3 · registry result, not featured evidence · combination headache 14.3% diarrhoea 14% nasopharyngitis 13.8% NCT02831673 · Phase 3 · registry result, not featured evidence · combination covid-19 6% syphilis 4% respiratory tract infection viral 3.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.6% upper respiratory tract infection 13.1% nasopharyngitis 12.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 83.9% blood creatinine increased 78.3% haemoglobin decreased 3.7% NCT03048422 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 89.8% blood creatinine increased 83.3% haemoglobin decreased 9.3% NCT03048422 · Phase 3 · registry result, not featured evidence · combination grade 3 bilirubinemia 0% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 50 mg OD headache 53.8% upper respiratory tract infection 38.5% diarrhoea 30.8% NCT01499199 · Phase 3 · registry result, not featured evidence 50mg BID diarrhoea 21.4% (placebo 12.5%) headache 21.4% (placebo 6.3%) lymphadenopathy 21.4% (placebo 0%) NCT01568892 · Phase 3 · registry result, not featured evidence cns disturbances 0% NCT01837277 · Phase 2/3 · registry result, not featured evidence 50 mg BID abnormal loss of weight 10% blood pressure increased 10% headache 10% NCT05630872 · Phase 2 · registry result, not featured evidence acute psychosis 1.5% (placebo 0%) incident pulmonary tuberculosis 1.5% (placebo 0%) acute kidney injury 0% (placebo 3.1%) NCT03991013 · Phase 2 · registry result, not featured evidence insomnia 5.7% (placebo 0%) NCT03851588 · Phase 2 · registry result, not featured evidence haemoglobin decreased 33.3% alanine aminotransferase increased 16.7% aspartate aminotransferase increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 50% alanine aminotransferase increased 16.7% blood bilirubin increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 83.3% neutrophil count decreased 50% acne infantile 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 42.9% blood bilirubin increased 35.7% dermatitis diaper 21.4% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 56.3% neutrophil count decreased 31.3% blood bilirubin increased 25% NCT05406583 · Phase 1 · registry result, not featured evidence hypokalaemia 71.4% (placebo 71.4%) hypoglycaemia 42.9% (placebo 71.4%) vivid dreams 28.6% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence hypokalaemia 62.5% (placebo 71.4%) cold 25% (placebo 14.3%) bloating 12.5% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence | 400 mg b.i.d.f upper respiratory tract infection 33% (placebo 24.4%) diarrhoea 32.6% (placebo 29.4%) fatigue 19.6% (placebo 15.1%) NCT00293254 · Phase 3 · combination show 17 more results400 mg b.i.d diarrhoea 31.9% (placebo 28.8%) nasopharyngitis 25% (placebo 17.8%) bronchitis 18.1% (placebo 13.6%) NCT00293267 · Phase 3 · combination alt elevation 55.3% NCT01147107 · Phase 4 · registry result, not featured evidence sleeping difficulties 52.6% (placebo 54.2%) gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%) headache 47.4% (placebo 33.3%) NCT03374358 · Phase 4 · registry result, not featured evidence runny nose 10.5% cold 5.3% diarrhoea 5.3% NCT03205566 · Phase 4 · registry result, not featured evidence nightmares and vivid dreams 13.2% diarrhoea 7.9% headache 7.9% NCT03205566 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 18.9% diarrhoea 10.8% abdominal cramps 5.4% NCT00939874 · Phase 4 · registry result, not featured evidence hyperbilirubinemia 3.8% (placebo 0%) NCT00843713 · Phase 4 · registry result, not featured evidence hyperbilirubinaemia 8.3% ocular icterus 8.3% bronchitis 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination gastrointestinal intolerance 9.1% neuropsychiatric side effect 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination neutropenia 6.7% diastolic hypertension 0% impaired fasting glucose 0% NCT01270802 · Phase 4 · registry result, not featured evidence bronchitis 20% diarrhea 20% headache 20% NCT00931801 · Phase 4 · registry result, not featured evidence · combination diarrhea 21.4% upper respiratory infection 21.4% fatigue 14.3% NCT00931801 · Phase 4 · registry result, not featured evidence · combination 1200 mg QD adverse event not related to the treatment 2.6% (placebo 5.6%) NCT03029689 · Phase 3 · registry result, not featured evidence · combination insomnia 8.2% amigdalitis 6.1% common cold 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cTrial phases differ: Phase 4 versus Phase 3.
- dPopulation context differs: registered conditions differ.
- ePopulation comparability has not been reviewed for 39 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dolutegravir
show 12 more results
show 3 more results
show 52 more results
show 3 more results
show 1 more result
+ 78 further endpoints in the CSV export.
Raltegravir
show 5 more results
show 1 more result
show 5 more results
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 7 more results
show 3 more results
+ 19 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dolutegravir's landscape · Raltegravir's landscape